IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation March 20, 2024
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline March 12, 2024
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target February 23, 2024